Who We Are-EN

Fundamental research and private companies together against COVID-19.

The MVM initiative originated in the international research project, The Global Argon Dark Matter Collaboration (GADM), which supports researchers looking for dark matter, an invisible component of the universe. This research includes experience with gas handling systems and complex control systems – the same capabilities required in hospital ventilators.

While in lockdown for the Covid-19 virus in Milan, Italy, Cristiano Galbiati, the spokesperson for the GADM Collaboration, recognized the need for additional ventilators early in the pandemic, and received government permission to develop a first prototype at the SAPIO Life s.r.l. ventilator repair and support center in Vaprio d’Adda, near Bergamo. With support from Italy’s National Institute for Nuclear Physics (INFN) and groups from the Universities of Milano Statale, Milano Bicocca, Napoli Federico II and Gran Sasso Science Institute (GSSI), and Elemaster S.p.A., AZ Pneumatica s.r.l., Saturn Magnetic s.r.l., Bel Power Europe s.r.l., and Nuclear Instruments s.r.l., they developed a first industrialized prototype, which fully demonstrated the viability of the conceptual design.
The collaboration expanded rapidly to include three national laboratories in Canada, including Canadian Nuclear Laboratories (CNL), TRIUMF and SNOLAB, through the leadership of Nobel laureate Dr. Art McDonald of Queen’s University. The US Collaboration includes people from Fermilab and the Princeton Plasma Physics Laboratory, two of the Department of Energy’s national laboratories as well as staff from US universities. The European collaboration also includes people from CNRS-IN2P3 and CIEMAT.

Getting the MVM ventilator to patients requires collaboration beyond nuclear and particle physicists. Government regulators, manufacturers and health care providers are also involved in the project.
To ensure the viability of the design in medical environments, clinical requirements are being developed with clinicians in the United States and Canada. Detailed testing and qualification of performance of the first prototype is underway with a breathing simulator at Ospedale San Gerardo in Monza, Italy and the Medicine Department of Milano Bicocca University.
The MVM Collaboration is being enthusiastically supported by industry members who are assessing part availability, evaluating supply chains, and who will eventually carry out the mass manufacturing. This process is already being supported by Elemaster in Italy. Canadian and American companies have been contacted to encourage their participation.
To facilitate rapid certification of the final design, additional direction is being provided by Health Canada, the US Air Force, the US FDA, and the Italian Istituto Superiore di Sanità and Consiglio Tecnico Scientifico della Protezione Civile.

The list of all MVM contributors and partners

A. Abba 29, P. Agnes 50, P. Amaudruz 4, M. Arba 19, F. Ardellier-Desages 6, C. Badia 15, G. Batignani 23,38, G. Bellani 35, G. Bianchi 32, D. Bishop 4, V. Bocci 24, W. Bonivento 19, B. Bottino 20, M. Bouchard 1, S. Brice 46, G. Buccino 15,43, S. Bussino 25, A. Caminata 20, A. Capra 4, M. Caravati 19, M. Carlini 15,43, L. Carrozzi 38, J. M. Cela Ruiz 41, B. Celano 22, C. Charette 1, V. Cocco 19, S. Coelli 21, M. Constable 4, G. Croci 35, S. Cudmore 1, S. D’Auria 21, A. Dal Molin 35, G. Davenio 26, S. De Cecco 24, L. De Laurentis 37, M. Del Tutto 46, J. deRuiter 1, A. Devoto 19, P. Diaz Gomez Maqueo 1, T. Dinon 32, E. Druszkiewicz 48, A. Fabbri 25, F. Ferroni 24, G. Fiorillo 22,36, R. Ford 3, G. Foti 35, D. Franco 6, F. Gabriele 27, C. Galbiati 47,28,15,19, P. Garcia Abia 41, L. Giarratana 30, J. Givoletti 12, M. Givoletti 12, F. Golf 52, G. Gorini 35, E. Gramellini 46, G. Grosso 16, F. Guescini 9, E. Guetre 4, T. Hadden 1, J. Hall 3, A. Heavey 46, G. Hersak 1, N. Hessey 4, An. Ianni 47, C. Ienzi 1, V. Ippolito 24, C. Kendziora 46, M. King 1, A. Kittmer 1, I. Kochanek 27, R. Kruecken 4, M. La Commara 22, G. Leblond 1, X. Li 47, C. Lim 4, T. Lindner 4, T. Lombardi 37, T. Long 1, S. Longo 17, P. Lu 4, G. A. Lukhanin 46, G. Magni 13, R. Maharaj 4, M. Malosio 32, C. Mapelli 31, P. Margetak 4, S. M. Mari 25, L. Martin 4, N. Massacret 4, A. McDonald 2, D. Minuzzo 10, T. Mohayai 46, L. Molinari Tosatti 32, C. Moretti 39, A. Muraro 16, F. Nati 35, T. Noble 3, A. Norrick 46, K. Olchanski 4, I. Palumbo 11, R. Paoletti 23,38, N. Paoli 12, S. Parmeggiano 33, L. Parmeggiano 33, C. Pearson 4, C. Pellegrino 17, V. Pesudo Fortes 41,42, A. Pocar 51, M. Pontesilli 14, S. Pordes 46, R. Pordes 46, A. Prini 32, O. Putignano 35, J. Raaf 46, M. Razeti 19, A. Razeto 27, D. Reed 45, A. Renshaw 50, M. Rescigno 24, F. Retriere 4, L. Rignanese 18, J. Rode 6,7, J. Romualdez 47,5, D. Sablone 27, R. Santorelli 41, E. Scapparone 18, T. Schaubel 1, B. Shaw 4, B. Slutsky 5, B. Smith 4, N. Smith 3, P. Spagnolo 23, F. Spinella 23, A. Stenzler 44, A. Steri 19, L. Stiaccini 34,23, C. Stoughton 46, P. Stringari 8, M. Tardocchi 16, R. Tartaglia 27, G. Testera 20, C. Tintori 12, A. Tonazzo 6, J. Tseng 54, E. Viscione 21, F. Vivaldi 12, J. Vossebeld 53, M. Wada 40, H. Wang 49, S. Westerdale 19, S. Yue 1, A. Zardoni 10

Canada
Canadian Nuclear Laboratories, Chalk River (1)
Queen’s University, Kingston (2)
Sudbury Neutrino Observatory Laboratory, Creighton Mine (3)
TRIUMF: Canada’s particle accelerator centre, Vancouver (4)
University of Toronto, Toronto (5)

France
APC, CNRS/IN2P3, Université de Paris, Paris (6)
LPNHE, CNRS/IN2P3, Sorbonne Université, Paris (7)
MINES ParisTech, Paris (8)

Germany
Max-Planck-Institut für Physik, Munich (9)

Italy
AZ Pneumatica S.R.L., Misinto (10)
Azienda Ospedaliera San Gerardo, Milano (11)
CAEN S.p.A., Viareggio (12)
Elemaster Group S.p.A., Lomagna (13)
Ginevri S.R.L., Roma (14)
Gran Sasso Science Institute, L’Aquila (15)
ISTP – CNR, Milano (16)
Istituto Nazione di Fisica Nucleare – CNAF, Bologna (17)
Istituto Nazione di Fisica Nucleare – Sez. di Bologna, Bologna (18)
Istituto Nazione di Fisica Nucleare – Sez. di Cagliari, Cagliari (19)
Istituto Nazione di Fisica Nucleare – Sez. di Genova, Genova (20)
Istituto Nazione di Fisica Nucleare – Sez. di Milano, Milano (21)
Istituto Nazione di Fisica Nucleare – Sez. di Napoli, Napoli (22)
Istituto Nazione di Fisica Nucleare – Sez. di Pisa, Pisa (23)
Istituto Nazione di Fisica Nucleare – Sez. di Roma 1, Roma (24)
Istituto Nazione di Fisica Nucleare – Sez. di Roma 3, Roma (25)
Istituto Superiore di Sanità, Roma (26)
Laboratori Nazionali del Gran Sasso, Assergi (27)
Museo della fisica e Centro studi e Ricerche Enrico Fermi, Roma (28)
Nuclear Instruments S.R.L., Lambrugo (29)
Policlinico San Pietro, Ponte San Pietro (30)
Politecnico di Milano, Milano (31)
STIIMA – CNR, Milano (32)
Sergio Installazioni Snc, Treviglio (33)
Universit`a degli Studi di Siena, Siena (34)
Università Milano Bicocca, Milano (35)
Università degli Studi Federico II, Napoli (36)
Università degli Studi dell’Aquila, L’Aquila (37)
Università di Pisa, Pisa (38)
Università di Roma La Sapienza, Roma (39)

Poland
Particle Astrophysics Science and Technology Centre (AstroCeNT), Warsaw (40)

Spain
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid (41)
Laboratorio Subterráneo de Canfranc, Canfranc (42)

Switzerland
CERN (Conseil Européen pour la Recherche Nucléaire), Genève (43)

USA
12th Man Technologies, Inc., Garden Grove (44)
Equilbar L.L.C., Fletcher (45)
Fermilab National Laboratory, Batavia (46)
Princeton University, Princeton (47)
Rochester University, Rochester (48)
University of California Los Angeles, Los Angeles (49)
University of Houston, Houston (50)
University of Massachussets, Amherst (51)
University of Nebraska-Lincoln, Lincoln (52)

United Kingdom
Liverpool University, Liverpool (53)
University of Oxford, Oxford (54)